BioSpace News Archive

Patients with febrile neutropenia are at a high risk of contracting the coronavirus infection.

The gonadotropin-releasing hormone is responsible for the release of follicle stimulating hormone and luteinizing hormone from the pituitary gland.

Diabetes is a group of metabolic diseases in which a person has a high blood glucose/sugar level either because of inadequate production of insulin in the body, or because of body cells not responding properly toward the insulin, or both.

Acne keloidalis is a type of chronic condition due to inflammation of hair follicle. Acne keloidalis usually occurs as an itchy bump at the back of the head or nape of the neck.

Q-nomy Inc., a leading global provider of omnichannel customer journey and customer experience optimization solutions, announced that all COVID-19 vaccinations across the U.K.

Kurin, Inc. has been named to Inc.’s inaugural Best in Business list in the Prosperous and Thriving category.

Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, yesterday reported initial data from an ongoing proof-of-concept clinical trial evaluating the safety and efficacy of OTL-201, an investigational ex vivo autologous hematopoietic stem cell (HSC) gene therapy being studied for the treatment of mucopolysaccharidosis type IIIA (MPS-IIIA, also known as Sanfilippo syndrome type A). The data were presented as part of an oral pres

Checkmate Pharmaceuticals , Inc. (NASDAQ: CMPI) (“Checkmate Pharmaceuticals”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced it has entered into a clinical collaboration agreement with Bristol Myers Squibb (NYSE: BMY) to evaluate the combination of Checkmate Pharmaceuticals’ CMP-001, a Toll-like receptor 9 (TLR9) agon

Peijia Medical (HK Stock Code: 09996) successfully commenced the animal experiment for its mitral valve edge-to-edge repair product, advancing the development to the next stage. The commencement of this experiment reflects Peijia Medical’s long term commitment in developing independent intellectual property products. Rather than a “

Prelude Corporation (PreludeDx ™ ), a leader in molecular diagnostics and precision medicine for early stage breast cancer, will present clinical outcomes data on the company’s commercially available test, DCISi